The incidence of major bleeding AEs in patients treated with prasugrel was 1.9% in PRASFIT-ACS , and was slightly lower in this study (1.6%). Furthermore, the incidences of minor bleeding AEs, clinically relevant bleeding AEs, other bleeding AEs, and all bleeding AEs were all lower in this study in comparison with PRASFIT-ACS . One possible explanation for these differences is that, in this study, intraoperative bleeding of the expected amount associated with invasive procedures, such as PCI, was not reported as an AE. Another possible explanation is that the observation period in this study differed from that in PRASFIT-ACS .